Immediate effects of docetaxel alone or in combination with epirubicin on cardiac function in advanced breast cancer

Anticancer Research

Volumn 23, Issue 2 C, 2003, Pages 1869-1873

  Syvanen, K ^a   Ekholm, E ^a   Anttila, K ^a   Salminen, Erva ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Docetaxel; Epirubicin; Heart rate variability; Left ventricular ejection fraction

Indexed keywords

DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; PREDNISOLONE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUPRAVENTRICULAR PREMATURE BEAT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; ECHOCARDIOGRAPHY; EPIRUBICIN; FEMALE; HEART; HEART RATE; HUMANS; MIDDLE AGED; PACLITAXEL; TAXOIDS; VENTRICULAR FUNCTION, LEFT;

EID: 0038199828     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Chan S: Cocetaxel vs. doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy. Oncology Huntington 11: 19-24, 1997.
2. Vanhoefer U, Cao S, Harstic A et al: Comparative antitumour efficacy of docetaxel and paclitaxel in nude mice bearing human tumour xenografts that overexpress the miltidrug resistance protein (MRP). Ann Oncol 8: 1221-1228, 1997.
3. Bissery M, Vrignaud P and Lavelle F: Preclinical profile of docetaxel (Taxotere): Efficacy as a single agent and in combination. Semin Oncol (6 suppl 13) 22: 3-16, 1995.
4. Ryberg M, Nielsen D, Skovsgaard T et al: Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16: 3502-3508, 1998.
5. Speyer J and Wasserheit C: Strategies for reducing cardiac toxicity. Semin Oncol 25: 525-537, 1998.
6. Meinardi MT, van der Graaf WTA, van Veldhuisen DJ et al: Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 25: 237-247, 1999.
7. McKillop JH, Bristow MR, Goris ML et al: Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 106: 1048-1056, 1983.
8. Marchandise B, Schroeder E, Bosly A et al: Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 118: 92-98, 1989.
9. Stoddard MF, Seeger J, Liddell NE et al: Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 20: 62-69, 1992.
10. Eaton GM, Cody RJ, Nunziata E et al: Early left ventricular dysfunction elicits activation of sympathetic drive and attenuation of parasympathetic tone in the paced canine model of congestive heart failure. Circulation 92: 555-561, 1995.
11. Wheeler T and Watkins PJ: Cardiac denervation in diabetes. Br Med J 4: 584-586, 1973.
12. Tjeerdsma G, Meinardi MT, van der Graaf ETA et al: Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 81: 419-423, 1999.
13. Casolo G, Balli E, Taddei T et al: Decreased spontaneous heart rate variability in congestive heart failure. Am J Cardiol 64: 1162-1167, 1989.
14. Keefe DL: Anthracycline induced cardiomyopathy. Sem Oncol 28: pp2-7, 2001.
15. Selvaratnam G, Phoilips R and Mohamed A: Cardiotoxicity of cytotoxic chemotherapy and its prevention. Adverse Drug React Toxicol 18: 61-105, 1999.
16. Gennari A, Salvadori B, Donati S et al: Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol 17: 3596-3602, 1999.
17. Dieras V: Docetaxel in combination with doxorubicin: a phase I dose-finding study. Oncology 11: 17-20, 1997.
18. Nabholz JM, Falkson G, Campos D et al: A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy to MBC. Proc Am Soc Clin Oncol 18: 127A (Abstr 485), 1999.
19. Nabholz JM, Mackey JR, Smylie M et al: Final results of a phase II study of docetaxel, doxorubicin, and cyclophosphamide (TAC) as 1st line chemotherapy in metastatic breast cancer patients. Breast Cancer Res Treat 50: 227 (abstr), 1998.
20. Sparano J, Hu P, Rao R, Falkson C, Wolff A and Wood W: Phase II trial of doxorubicin and paclitaxel plus GSC-F in metastatic breast cancer: Eastern Cooperative Oncology Group. J Clin Oncol 17: 3828-3834, 1999.
21. Pagani O, Sessa C, Nole F et al: Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Ann Oncol 11: 985-991, 2000.
22. Sessa C and Pagini O: Docetaxel and epirubicin in advanced breast cancer. Oncologist 6 Suppl 3: 13-16, 2001.
23. Misset J, Dieras V, Gruia G, Bourgeios H, Cvitkovic E, Kalla S, Bozec L, Beuzeboc P, Jasmin C, Aussel J, Riva A, Azli N and Pouillart P: Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 10: 553-560, 1999.